Edwards Lifesciences projected its fiscal 2026 adjusted profit above consensus estimates, reflecting confidence in its core structural heart and critical care franchises. The company expects continued margin expansion as procedural volumes recover globally.

Robust demand for artificial heart valves, including transcatheter aortic valve replacement systems, and increased uptake of critical care monitoring devices underpin the bullish outlook. Management highlighted strong order trends in North America and Europe.

Investors rewarded the forecast with a 3% gain in after-hours trading, signaling approval of the company’s ability to exceed profit expectations. The stock move reflects optimism that device demand will sustain revenue growth through 2026.